

AWARD NUMBER:

W81XWH-22-1-0518

TITLE:

Biomarkers of Response to Combination Cabozantinib + Nivolumab in Advanced Renal Cell Carcinoma

PRINCIPAL INVESTIGATOR:

Toni K Choueiri

CONTRACTING ORGANIZATION:

Dana-Farber Cancer Institute
Boston, MA

REPORT DATE:

July 2023

TYPE OF REPORT:

Annual

PREPARED FOR: U.S. Army Medical Research and Development Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release; Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. **PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.**

1. REPORT DATE July 2023		2. REPORT TYPE Annual		3. DATES COVERED 01Jul2022-30Jun2023	
4. TITLE AND SUBTITLE Biomarkers of Response to Combination Cabozantinib + Nivolumab in Advanced Renal Cell Carcinoma				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-22-1-0518	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Toni K Choueiri & Sabina Signoretti				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Dana-Farber Cancer Institute Boston, MA 02215 Brigham and Women's Hospital Boston, MA 02215				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Development Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT Immune checkpoint inhibitors (ICI) have changed the treatment management of metastatic clear cell renal cell carcinoma (mccRCC). However, many patients do not experience durable benefit. Thus, we aim to explore the clinical utility of previously identified biomarkers selecting ICI+VEGF-TKI therapy vs. VEGF-TKI therapy alone using specimen collection from phase III trial CheckMate 9ER. For markers that we successfully replicate the associative effect, we plan on developing a predictive model for patients treated with ICI+VEGF-TKI that can help clinicians estimate the probability that an event will occur. Model replication will be performed using specimens and clinical data from clinical trial JAVELIN Renal 101. In addition, we will also explore the potential associations that were previously uncovered between RNA-based or protein-based biomarkers and resistance to ICI monotherapy that may be overcome when combined with an VEGF-TKI using trials HCRN and OMNIVORE.					
15. SUBJECT TERMS Clinical biomarkers Immunotherapies					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT Unclassified	b. ABSTRACT Unclassified	c. THIS PAGE Unclassified			USAMRDC
			Unclassified	11	19b. TELEPHONE NUMBER (include area code)

TABLE OF CONTENTS

	<u>Page</u>
1. Introduction	4
2. Keywords	4
3. Accomplishments	4
4. Impact	7
5. Changes/Problems	7
6. Products	7
7. Participants & Other Collaborating Organizations	8
8. Special Reporting Requirements	11
9. Appendices	11

1. INTRODUCTION:

Immune checkpoint inhibitors (ICI) have changed the treatment management of metastatic clear cell renal cell carcinoma (mccRCC). However, many patients do not experience durable benefit. Thus, we aim to explore the clinical utility of previously identified biomarkers selecting ICI+VEGF-TKI therapy vs. VEGF-TKI therapy alone using specimen collection from phase III trial CheckMate 9ER. For markers that we successfully replicate the associative effect, we plan on developing a predictive model for patients treated with ICI+VEGF-TKI that can help clinicians estimate the probability that an event will occur. Model replication will be performed using specimens and clinical data from clinical trial JAVELIN Renal 101. In addition, we will also explore the potential associations that were previously uncovered between RNA-based or protein-based biomarkers and resistance to ICI monotherapy that may be overcome when combined with an VEGF-TKI using trials HCRN and OMNIVORE.

2. KEYWORDS:

Clinical biomarkers; Immunotherapies; Systemic therapies – discovery and development; Translational Research

3. ACCOMPLISHMENTS:

What were the major goals of the project?

Below is a list of major tasks and subtasks according to Specific Aims outlined in the grant proposal's SOW. Accomplishments and updates at this time are detailed in **bold** for this first annual report.

Tasks according to Aims
Subtask 1: Submit documents for institutional IRB review.
<i>Milestone #1: IRB approval received. This has been completed.</i>
Subtask 2: Submit IRB approval and necessary documents for HRPO review.
<i>Milestone #2: HRPO approval received. This has been completed.</i>
Subtask 3: • To obtain individual level clinical data CheckMate 9ER (CM9ER), JAVELIN Renal 101, HCRN and OMNIVORE. This has been completed.
Specific Aim 1: To identify immune cell populations in the ccRCC microenvironment that predict response or resistance to ICI+VEGF combination therapy.
Major Task 1 (Aim 1a): To demonstrate that mildly exhausted CD8 ⁺ tumor infiltrating lymphocytes predict response to ICI+VEGF therapy.
Subtask 4: To score PD-L1 immunohistochemistry (IHC) and to validate IF image analysis results; To extract RNA in tumor areas; To assess immunophenotype of CD8 ⁺ PD-1 ⁺ TIM-3 ⁻ LAG-3 ⁻ cells via multiplex IF and image analysis. Human Anatomical Substances (HAS) used: de-identified tissue tumor samples from CM9ER. <u>Prior to shipping the specimens, BMS took measures to ensure that the subset of patients who consented to FFPE collection during the trial were not different compared to the overall, intent-to-treat population, with respect to progression-free survival endpoint. For this purpose, survival analyses were produced and compared between subsets. Upon successful completion of the analyses which showed that both cohorts shared similar event rates, BMS sent the unstained slides to the Signoretti Lab in May 2023.</u>
Subtask 5: To correlate IF biomarker with clinical outcome

<p>Major Task 2 (Aim 1b): To discover novel immune cell types and/or pathways specific to immune cells that are associated with response or resistance to ICI+VEGF therapy using high-definition spatial proteomics (exploratory).</p>
<p>Subtask 6: To use MIBI to identify cell populations and interactions. Human Anatomical Substances (HAS) used: de-identified tissue tumor samples from CM9ER. <u>We are currently working with BMS to receive tissue samples for the high-plex proteomic studies.</u></p>
<p>Subtask 7: To correlate novel immune cell types with clinical outcomes.</p>
<p><i>Milestone #3: Aim 1 completed; manuscript preparation and submission</i></p>
<p>Specific Aim 2: To identify gene signatures and genomic alterations that predict response to ICI+VEGF combination therapy in mcrRCC</p>
<p>Major Task 3 (Aim 2a): To demonstrate that high levels of high T-effector and/or cell-cycle gene signatures predict response to ICI+VEGF combination therapy</p>
<p>Subtask 8: To perform RNA-seq/WES analysis of tumor samples to characterize molecular clusters of cell-cycles and T-eff signature. Human Anatomical Substances (HAS) used: de-identified WES/RNA samples used from CM9ER. <u>BMS sent WES/RNAseq data to the Choueiri/Braun Labs in April 2023.</u></p>
<p>Subtask 9: To correlate levels of T-eff and/or cell-cycle gene signatures with clinical outcomes</p>
<p>Major Task 4 (Aim 2b): To demonstrate that high levels of myeloid cell-associated genes identify patients that are refractory to anti-PD1 monotherapy but can respond to ICI+VEGF combination therapy.</p>
<p>Subtask 10: To perform RNA-seq of tumor samples to assess myeloid cells. Human Anatomical Substances (HAS) used: de-identified WES/RNA samples from CM9ER and HCRN+OMNIVORE. <u>As noted in Subtask 8, WES/RNAseq data for the CM9ER trial has been sent to Choueiri/Braun Labs. With regards to data of the OMNIVORE trial, we observed that some samples were previously shipped to an off-site storage for logistical reasons. In a research meeting, it was determined that 96 frozen OCT-embedded samples were currently available for analyses. Additional steps are being taken to populate additional samples. Determination of the finalized inventory is currently ongoing and expected to be produced at the next meeting (end of July 2023). As for HCRN samples, WES and RNAseq data have already been generated by the Signoretti/Braun groups.</u></p>
<p>Major Task 5 (Aim 2c): To demonstrate that loss of 9p21.3 in the context of immune cell infiltration identifies patients that are refractory to anti-PD1 monotherapy but can respond to ICI+VEGF combination therapy</p>
<p>Subtask 11: loss of 9p21.3 will be assessed via WES analysis of tumor and normal specimens. Human Anatomical Substances (HAS) used: de-identified WES/RNA samples from CM9ER and HCRN+OMNIVORE.</p>
<p><i>Milestone #4: Aim 2 completed; manuscript preparation and submission</i></p>
<p>Specific Aim 3: To develop and externally validate a model for prediction of PFS using biomarkers and conventional clinic-pathologic variables</p>
<p>Subtask 12: To develop a prognostic model for prediction of PFS at 6 month and at 12 month in patients treated with nivo+cabo from the CM9ER cohort, using clinic-pathologic variables and candidate biomarkers (those that replicated in Aims 1 and 2a). The most optimal model will be selected based on measures of predictive accuracy (discrimination, calibration, goodness of fit, reclassification). Exploratory endpoints will include OS. Model validation will be performed in the ave+axi arm from the JAVELIN cohort.</p> <p>Human Anatomical Substances (HAS) used: de-identified WES/RNA samples from CM9ER and JAVELIN. <u>WES/RNAseq data and clinical data for both the CM9ER and JAVELIN trials have been received and are available for the development and external validation of the predictive model.</u></p>
<p><i>Milestone #5: Aim 3 completed; manuscript preparation and submission</i></p>

What was accomplished under these goals?

We have obtained tissue specimens as well as WES and RNAseq data for correlatives and linked clinical data from the primary phase III trial (CM9ER), as previously planned in the SOW. Similarly, WES and RNAseq data as well as clinical data were obtained for JAVELIN Renal 101, which will serve as our replication cohort when the time comes. While the final number of specimens is still being determined for HCRN+OMNIVORE, we are still on-schedule as the use of these specimens will only come at the end of year 2 (as previously planned). Of note, WES and RNAseq data have already been generated for the HCRN trial.

What opportunities for training and professional development has the project provided?

Nothing to report.

How were the results disseminated to communities of interest?

Nothing to report.

What do you plan to do during the next reporting period to accomplish the goals?

Within the next 12 months, we will proceed with the Aims and sub-aims as proposed in the SOW.

Specific Aim 1: To identify immune cell populations in the ccRCC microenvironment that resistance to ICI+VEGF combination therapy.

Major Task 1 (Aim 1a): To demonstrate that mildly exhausted CD8⁺ tumor infiltrating lymphocytes predict response to ICI+VEGF therapy.

For this purpose, the Signoretti Lab will first proceed to and perform multiplex immunofluorescence staining of the tissue samples. The immunophenotype of CD8⁺ PD-1⁺ TIM-3⁻ LAG-3⁻ cells will be assessed by image analysis and validation by a pathologist. The biomarker will then be correlated with clinical outcomes using CM9ER. Scoring PD-L1 immunohistochemistry will also be performed. Results of IF and ICH analyses will be correlated with clinical outcomes. We do not anticipate any issues at this point.

Major Task 2 (Aim 1b): To discover novel immune cell types and/or pathways specific to immune cells that are associated with response or resistance to ICI+VEGF therapy using high-definition spatial proteomics (exploratory).

For this task, the Signoretti Lab will obtain the tissue samples through a collaboration with BMS. They will then perform high-plex proteomic analyses to identify cell type and states as well as spatial interactions correlated with clinical outcomes using tissue samples CM9ER.

Specific Aim 2: To identify gene signatures and genomic alterations that predict response to ICI+VEGF combination therapy in ccRCC.

Major Task 3 (Aim 2a): To demonstrate that high levels of high T-effector and/or cell-cycle gene signatures predict response to ICI+VEGF combination therapy.

The Choueiri/Braun Labs will perform analyses of the RNAseq data from the CM9ER trial to determine molecular clusters of cell-cycles and T-effector signatures and then test their association with clinical outcomes.

Major Task 4 (Aim 2b): To demonstrate that high levels of myeloid cell-associated genes identify patients that are refractory to anti-PD1 monotherapy but can respond to ICI+VEGF combination therapy.

The Choueiri/Braun Labs will obtain RNAseq data from tumor samples from OMNIVORE trial. RNAseq data from the CM9ER trial and the pooled cohort of the HCRN and OMNIVORE trials will then be analyzed to test the hypothesis that high levels of myeloid cell-associated genes are associated with poor outcomes in patients from the HCRN and OMNIVORE trials but not in patients from the CM9ER trial.

4. **IMPACT:**

What was the impact on the development of the principal discipline(s) of the project?

Nothing to report.

What was the impact on other disciplines?

Nothing to report.

What was the impact on technology transfer?

Nothing to report.

What was the impact on society beyond science and technology?

Nothing to report.

5. **CHANGES/PROBLEMS:**

Changes in approach and reasons for change

Nothing to report.

Actual or anticipated problems or delays and actions or plans to resolve them

Nothing to report.

Changes that had a significant impact on expenditures

Nothing to report.

Significant changes in use or care of human subjects, vertebrate animals, biohazards, and/or select agents

Nothing to report.

Significant changes in use or care of human subjects

Nothing to report.

Significant changes in use or care of vertebrate animals

Nothing to report.

Significant changes in use of biohazards and/or select agents

Nothing to report.

6. **PRODUCTS:**

Nothing to report.

Books or other non-periodical, one-time publications.

Nothing to report.

Other publications, conference papers and presentations.

Nothing to report.

- **Website(s) or other Internet site(s)**

- Nothing to report.

- **Technologies or techniques**
 - Nothing to report.

- **Inventions, patent applications, and/or licenses**
 - Nothing to report.

- **Other Products**
 - Nothing to report.

7. PARTICIPANTS & OTHER COLLABORATING ORGANIZATIONS

What individuals have worked on the project?

The following individuals are either Principal Investigators, or have worked at least one person month per year on the project for the Year 1 reporting period:

DFCI:

- Toni Choueiri, Principal Investigator (no change)
- Meredith Regan, Co-Investigator (no change)
- Maxine Sun, Statistician (no change)
- Chris Labaki, Postdoctoral Fellow (no change)
- Kyler Berlind, Research Technician (previously not listed, 4 person months): Helped coordinate specimens at the Gelb Center (for HCRN+OMNIVORE)

YALE:

- David Braun, Subaward Investigator (no change)

Has there been a change in the active other support of the PD/PI(s) or senior/key personnel since the last reporting period?

Choueiri:

Completed:

DoD W81XWH-19-1-0553/KC180206 (Choueiri)

DoD W81XWH-19-1-0551/KC180129 (Choueiri)

New:

NCI/NIH

R01CA266424 (Choueiri, Signoretti) 07/01/22-06/30/27

Tissue-based biomarkers of anti-PD-1-based therapy in metastatic renal cell carcinoma

DoD TRPA KC220072 (Rizwan Romee, Wenxin Xu) 09/01/2023-08/31/25

Mechanisms and predictors of adoptive cytokine-induced memory-like NK cell therapy in renal cell carcinoma

Regan:

Completed:

Saverin Breast Cancer Research Fund (DFCI Internal Award) 6/15/20-6/30/23, Regan, MM; Tyekucheva, S

Critical Assessment of Tissue Source for DNA sequencing in ER+/HER - Metastatic Breast Cancer

New:

ETOP IBCSG Partners Foundation Renewal (through Frontier Science & Technology Research Foundation), Regan, MM

1/1/23-12/31/23, IBCSG Statistical and Data Management Center

NCI- 1R01CA266424-01A1, Choueiri, T; Signoretti, S, 7/1/22-6/30/27

Tissue-based biomarkers of anti-PD-1-based therapy in metastatic renal cell carcinoma

Bristol-Myers Squibb, CA209-1181 ,Regan, MM, 11/7/22-10/6/24

Treatment-Free Survival (TFS) in Advanced Renal Cell Carcinoma Patients Receiving Nivolumab and Cabozantinib Combination

Sun:

Completed:

None.

New:

NCI/NIH

R01CA266424 (Choueiri, Signoretti) 07/01/22-06/30/27

Tissue-based biomarkers of anti-PD-1-based therapy in metastatic renal cell carcinoma

Braun

Completed:

None.

New:

NCI/NIH

R01CA266424 (Choueiri, Signoretti) 07/01/22-06/30/27

Tissue-based biomarkers of anti-PD-1-based therapy in metastatic renal cell carcinoma

NCI/NIH

5P50CA101942-18 (McDermott, Kaelin) 09/2022 – 08/2023

Evaluating the Impact of Belzutifan on T Cell Phenotype and Function

Kidney Cancer Association

23-001032 (Braun) 10/2022 – 10/2023

Dissecting the immunobiology of chromophobe renal cell carcinoma using single-cell transcriptomics

AstraZeneca

GR118592 / AWD0008843 (Braun) 12/2022 – 11/2024

Patient-derived tumor models of renal cell carcinoma for the evaluation of novel immunotherapies

NIH/NCI

R01CA279822 / R37CA279822 (Braun) 04/2023 – 03/2028

Tumor and immune determinants of effective anti-tumor immunity in renal cell carcinoma

DoD/USAMRAA

KC220016 (Braun) 09/2023 – 08/2026

Uncovering the Tumor-Immune Microenvironmental Determinants of Immunotherapy Response in Renal Cell Carcinoma Through Ex Vivo Patient-Derived Models

8. SPECIAL REPORTING REQUIREMENTS

COLLABORATIVE AWARDS:

Not applicable.

QUAD CHARTS:

Not applicable.

9. APPENDICES:

Not applicable